Kimberly Spencer
Family · Coolville, OHNPI 1588684740
Payments from drug & device makers
Across 71 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$255
- Novo Nordisk$184
- AbbVie$161
- Abbott$111
- Astellas Pharma US Inc$80
- Lilly USA, LLC$65
- plus $449 from 14 others
What the payments were for
- Food & beverage$1,305100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 12 | $255 |
| Novo Nordisk | 11 | $184 |
| AbbVie | 9 | $161 |
| Abbott | 6 | $111 |
| Astellas Pharma US Inc | 5 | $80 |
| Lilly USA, LLC | 4 | $65 |
| Corcept Therapeutics | 3 | $57 |
| Medtronic | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| AstraZeneca | 2 | $30 |
| Exact Sciences | 1 | $25 |
| Merck | 1 | $25 |
| Alkermes, Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Biogen | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Novartis | 1 | $18 |
How this compares
$1,305 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $143,174 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $63,227 |
| FarxigaDapagliflozin Propanediol | 36 | $57,116 |
| CreonLipase/Protease/Amylase | 21 | $50,416 |
| EliquisApixaban | 36 | $47,299 |
| XareltoRivaroxaban | 35 | $43,856 |
| LinzessLinaclotide | 24 | $31,176 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $24,773 |
| Spiriva RespimatTiotropium Bromide | 24 | $22,528 |
| JardianceEmpagliflozin | 13 | $18,244 |
| MyrbetriqMirabegron | 14 | $12,640 |
| DuleraMometasone/Formoterol | 12 | $8,325 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $7,306 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $4,731 |
| Levothyroxine Sodium | 182 | $3,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $184 | $143,17485 claims |
| AbbVieCreon, Linzess | $161 | $81,59245 claims |
| AstraZenecaFarxiga | $30 | $57,11636 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $12,64014 claims |
| MerckDulera | $25 | $8,32512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.
Other family in Coolville
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.